tbuckley/cabot-search huggingface dataset:
685TiP A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Authors: M.C. Mata Fernandez, K.J. Cohen, S. Melnyk, A. Rotger, T. Thevenet
Journal: Annals of Oncology (2024)
667P Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Authors: D.G. Knapen, C.A.J. van Winkel, T. Grevelink, J. van Sluis, M. Lub-de Hooge, A. Brouwers, M. van der Vegt, J. Pizzey, R. Williams, S. Archer, P. Bland-Ward, K. Duffy, K. Hashimoto, D.J. de Groot, E.G.E. de Vries
Journal: Annals of Oncology (2024)
694P Sequential high-dose-chemotherapy with 4 cycles paclitaxel, ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory male germ cell cancer: Final results with 15.8 years follow-up
Authors: H.J.E-V. Schmoll, T. Kegel, K. Jordan, F.M. Meinert, F. Cygon, K. Hammad
Journal: Annals of Oncology (2024)
681TiP A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Authors: L.S. Rosen, N. Azad, R. Costa, F. Meric-Bernstam, H. Alaoui, D.M. Jablons, P. Munster, E.P. Hamilton
Journal: Annals of Oncology (2024)
608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
Authors: W. Park, A. Kasi, A.I. Spira, J.D. Berlin, J.S. Wang, B. Herzberg, Y. Kuboki, S. Kitano, M. Pelster, J.W. Goldman, D. Morgensztern, S. Kondo, P.A. Jänne, H. Fujii, H-J. Lee, S. Gill, A. Saci, P. Lorusso, A.W. Tolcher
Journal: Annals of Oncology (2024)
671P LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Authors: J. McConathy, Y. Menda, J. Rodon, A.H. Goenka, R.H. Moy, S. Morse, A. Demange, P. Aimone, T.A. Hope
Journal: Annals of Oncology (2024)
583P COMPReS study: Multiomic profiling reveals organ-specific differences in metastases and identifies novel predictive biomarkers in relapsed localized colon cancer
Authors: B. García-Mico, F. Gimeno-Valiente, J. Martin-Arana, B. Martínez-Castedo, D.G. Camblor, M. García-Bartolomé, B. Palomar, C. Martinez Ciarpaglini, M. Cabeza Segura, V. Gambardella, J.F. Català-Senent, D. Moro, S. Garcia-Botello, L. Pérez, S. Rosello Keranen, T.C. Fleitas, M. Huerta, D. Roda Perez, A. Cervantes, N. Tarazona Llavero
Journal: Annals of Oncology (2024)
646P A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Authors: C.J. Twelves, U. Banerji, W.D. Tap, N. Cook, T.R.J. Evans, R. Plummer, A. Anthoney, C. Plummer, R. Dawson, P. Loadman, G. Lahu, H. Jones, N. Kinnersley, R. Edwards, G. Gordon, L.D. Cranmer
Journal: Annals of Oncology (2024)
675P Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Authors: L. Shen, D. Liu, J.J.W. Park, Z. Zhao, B. Gao, B. Liu, J. Wu, J. Zhang, H. Zong, J. Ruan, X. Zhang, J. Dai
Journal: Annals of Oncology (2024)
665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Authors: T. Marron, J. Segar, J.D. Berlin, R. Boccia, A.I. Spira, J. Powderly, C. Chen, Z.A. Wainberg, J.M. Schanzer, J. Glenn, K. Klumpp, I. Csiki, J.G. Misleh
Journal: Annals of Oncology (2024)
647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
Authors: E. Fontana, J.S. Wang, M. Mckean, R. Aljumaily, J-P. Machiels, B. Doger de Spéville, M. Vieito, L. Carter, H. Prenen, G.S. Falchook, A. Greystoke, W.I. Ortuzar Feliu, A. De, X. Gu, M. Li, A. de Rienzo, B. Bashir
Journal: Annals of Oncology (2024)
598TiP PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Authors: T. Aparicio, A. Turpin, A. Zaanan, C. de la Fouchardiere, K. Le Malicot, S. Lonardi, D.P. Modest, R.H. Wilson, A. Ballhausen, J. Graham, M. Guarssifi, M. Svrcek, P. Laurent-Puig, S. Manfredi
Journal: Annals of Oncology (2024)
684TiP A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Authors: B. Keam, J-H. Ahn, K. Kim, S-H. Hong, V. Ganju, L.E. Lim, V. Kwatra, A. Body, P.D. Rhee, S. Jung, J. Yoon, E. Baek, Y.S. Noh
Journal: Annals of Oncology (2024)
650P Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors
Authors: K.P. Papadopoulos, A. Dowlati, J.S. Lopez, J. Rodon, A.I. Spira, M. Stein, M. Zibelman, W.I. Ortuzar Feliu, A. Dickson, A. De, X. Gu, H. Cohen, M. Li, J. Bader, C. Bray, S. Santos, J. Smith, R. Lis, T.R.J. Evans
Journal: Annals of Oncology (2024)
596P Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study
Authors: N. Heersche, J.E. Knikman, M. De With, M. Lopez-Yurda, A. Baars, G-J. Creemers, H. Droogendijk, E. Fiets, M. Deenen, R. Van Schaik, B. van den Bosch, E. Oomen-de Hoop, H. Rosing, J. Swen, H. Gelderblom, J.H.M. Schellens, J.H. Beijnen, R.H. Mathijssen, H-J. Guchelaar, A. Cats
Journal: Annals of Oncology (2024)
670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Authors: M. Wermke, V. Gambardella, Y. Kuboki, E. Felip, M.F. Sanmamed, O. Alese, C.M. Sayehli, E. Arriola Aperribay, J. Wolf, L. Villaruz, M. Studeny, M. Bouzaggou, X. Fang, D. Morgensztern
Journal: Annals of Oncology (2024)
638P Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Authors: A.M. Tsimberidou, S. Fu, D.S. Hong, S.A. Piha-Paul, A. Naing, J. Rodon, T.A. Yap, D. Karp, E.E. Dumbrava, J.V. Heymach, J.A. Ajani, C. Cartwright, J. BecK, C. Andersen, M. Kahle, D. Vining, J.S. Ross, C. Chao, D.A. Berry, F. Meric-Bernstam
Journal: Annals of Oncology (2024)
630P Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Authors: H. Gelderblom, O. Saavedra Santa Gadea, M. Jalving, I. Desar, J.A. Gietema, A. Oberoi, C. Van Herpen, J.R. Kroep, R. Frederiksen Franzen, A. Bellon, S. Micallef, T. Tat, V. Dozio, N. Luong, E. Rodrigo Imedio
Journal: Annals of Oncology (2024)
628P Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Authors: D.S. Hong, R-H. Xu, L. Shen, M.P. Dierselhuis, D. Orbach, R.S. McDermott, A. Italiano, M. Tahara, V. Bernard-Gauthier, N. Neu, C.E. Mussi, E.A. De La Cuesta, T. Laetsch, A.E. Drilon
Journal: Annals of Oncology (2024)
607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors
Authors: M. Oliva, S. Ochsenreither, C. Le Tourneau, S. Champiat, R. Saleh, K. Burkitt, L. Nabell, N. Steeghs, A. Spreafico, A.R. Minchom, A. Patnaik, J.A. Call, E. Fontana, N. Kotecki, E. Garralda, A. Zivi, J.W. Riess, S. Gupta, R. Zhang, M. Gillison
Journal: Annals of Oncology (2024)
603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
Authors: R. Guo, A. Dowlati, I. Dagogo-Jack, J. Vibert, A.I. Spira, V. Moreno Garcia, S. Punekar, E. Calvo, G.P. Sonpavde, M. Awad, J.W. Riess, T.C. Hernandez Guerrero, B. Herzberg, A. Italiano, A. Swalduz, P. Lorusso, E.F. Smit, E.B. Garon, W. Novotny, T.A. Yap
Journal: Annals of Oncology (2024)
605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Authors: H. Zhao, Y. Ma, X. Meng, L. Wu, Y. Fan, Y. Zheng, Z. Liu, Y. Ji, D. Lv, S. Luo, D. Sommerhalder, S. Fu, Y. Huang, Y. Yang, W. Fang, Y. Zhao, Y. Wang, S. Chin, T. Xue, L. Zhang
Journal: Annals of Oncology (2024)
669P CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Authors: P. Lorusso, F. Meric-Bernstam, N. Hafez, I.I. Rodriguez Rivera, D. Tripathy, S. Wilks, P. Pearson, M.N. Needle, A.W. Tolcher
Journal: Annals of Oncology (2024)
614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification
Authors: M. Vieito, E. Garralda, I. Mehmi, C. Gaudy Marqueste, B.H. O’Neil, T.M. Medina, A. Body, A.M. Arance, S. Kummar, Y.G. Najjar, P.L. Bedard, C. Chu, C. McKenna, S. Hume, L.M. Kopp, J. Lee
Journal: Annals of Oncology (2024)
611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors
Authors: J.B.A.G. Haanen, A. Mackensen, C. Schultze-Florey, W. Alsdorf, E. Wagner-Drouet, D. Heudobler, P. Borchmann, A. Busse, S. Mielke, S. Bins, G. Ungerechts, C. Bokemeyer, S. Klobuch, N. Kutsch, F. Müller, A. Desuki, W. Zhong, L. Preussner, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2024)
636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Authors: B.Y. Kong, F.P-Y. Lin, D. Espinoza, S. Thavaneswaran, T. Meniawy, J. Desai, R. Harrup, S. Selva-Nayagam, M. Charakidis, K. Cuff, L. Sebastian, C.K. Lee, S. Chinchen, D.M. Thomas, M.L. Ballinger, J. Simes, D. Goldstein
Journal: Annals of Oncology (2024)
625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Authors: M. Fakih, D. Sohal, J.A. Call, S. Ulahannan, A.B. El-Khoueiry, T.C. Hernandez Guerrero, T.B. Karasic, A.I. Spira, M. Zhong, H. Merrit, K. Hari, O.C. Trifan, N. Dhawan
Journal: Annals of Oncology (2024)
686TiP Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma
Authors: Q. Wang, X. Chai, R. Lin, L. Zheng, D. Cao, X. Qu, L. Liu, L. Wu, H. Mou, Q. Xu, J. Shi
Journal: Annals of Oncology (2024)
654P Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Authors: B. Doger de Spéville, M. Mckean, C. Baldini, A. Italiano, O. Reig Torras, E. Fontana, L. Verlingue, B. Bashir, J.S. Wang, L. DeMars, K. Josephs, W.I. Ortuzar Feliu, A. De, X. Gu, C. Xu, M. Li, L. Carter
Journal: Annals of Oncology (2024)
648P An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors
Authors: D. Liu, L. Shen, Y. Sun, N. Li, O. Marathe, R. Huang, J. Shao, M. Xu, B. Pan, F. Pan, S. Gao, J. Gong
Journal: Annals of Oncology (2024)
585P Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Authors: N.W. Marschner, J. Uhlig, L. Jacobasch, L. Mueller, M. Reiser, A. Schuch, L. Serrer, R. de Buhr, H.U. Siebenbach, T. Göhler, J.K. Schröder, D. Semsek, A. Koehler, P. Stübs, K.M. Potthoff
Journal: Annals of Oncology (2024)
663P First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Authors: M.A. Khattak, R.J. Sullivan, M. Gutierrez, A. Jimeno, S.S. Thomas, G.V. Long, S. Kummar, A. Daud, A. Rohatgi, R.F. Sweis, J.E. Bauman, V. Boni, S. Parakh, H.N. Daghestani, J. Xu, Y. Li, M. Morrissey, M. Abadier, F. Barlaskar, D. Sarker
Journal: Annals of Oncology (2024)
627P Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Authors: A.E. Drilon, R-H. Xu, C.M. van Tilburg, F. Doz, D.S.W. Tan, J.J. Lin, B. Geoerger, C.M. Zwaan, U.N. Lassen, A. Italiano, S. Kummar, R.S. McDermott, D-I. Burcoveanu, N. Neu, N. Brega, T. Laetsch, D.S. Hong, L. Shen
Journal: Annals of Oncology (2024)
731P Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Authors: M.R. Mirza, C. Mathews, L. Gilbert, L. Bjorge, K. Ring, M.M. Pishchyk, K. Pennington, Y. Segev, M.A. Powell, T. Van Gorp, D. Bender, K. Schneider, R. Miller, A. Armstrong, G. Canturia, R. Gogoi, G. Antony, S. Stevens, G. Valabrega, L.M. Landrum
Journal: Annals of Oncology (2024)
644P Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer
Authors: T. Deng, Y. Sun, B. Wang, J. Zhang, C. Zhou, J. Wang, H. Yang, B. Yang, J. Wei, R. Lin, J. Liu, E. Li, Y. Ji, L. Wang, X. Wang, Z. Li, Y. Yang
Journal: Annals of Oncology (2024)
624P Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Authors: R. Dziadziuszko, S. Damian, S. Gadgeel, E. Garralda, A. Italiano, J.E. Kim, M. Krzakowski, C-C. Lin, A. Popovtzer, D. Thomas, W. Kirschbrown, S. Patel, T. Pham, M. Sbirnac, F. Wu, F. Barlesi
Journal: Annals of Oncology (2024)
597P Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Authors: F.L. Simões, F. Fonseca, J.G. Magalhaes, C.S. Pinto, A.R. Fortuna, S. Carvalhal, M. Limbert, N.C. Abecasis, M.J. Bouw
Journal: Annals of Oncology (2024)
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Authors: S. Blagden, M. Elshani, S.N. Symeonides, A. Skolariki, N.R. Haris, Z.Y. Boh, A. Dickson, I.H. Um, Y. Zhang, F.G. McKissock, E. Oelmann, J. Bloss, N. Cook, T.R.J. Evans, R. Plummer, D.J. Harrison
Journal: Annals of Oncology (2024)
656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Authors: V. Moreno Garcia, D-Y. Oh, M.H. Ryu, E. Calvo, E. Garralda, W-P. Chung, L-Y. Bai, K.I. Rojas Laimito, O. Yildirim, S. Masciari, G. Mi, L. Wang, P. Kanlikilicer, B. Buday, F. Rharbaoui, G. Abbadessa, E.E. Dumbrava
Journal: Annals of Oncology (2024)
652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Authors: O. Reig Torras, L. Crouzet, A. Necchi, C. Baldini, M.J. Lostes Bardaji, B. Doger de Spéville, A. Italiano, L. Verlingue, V. Boni, L. Carter, I. Duran, B. Garmezy, M.D. Galsky, G.S. Falchook, L. DeMars, K. Josephs, C. Xu, J. Bader, E. Fontana
Journal: Annals of Oncology (2024)
626P Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Authors: A.M. Di Giacomo, M. Simonelli, F. Santangelo, G. Amato, E. Simonetti, J. Graham, M. Lahn, G. Di Conza, T. Hammett, R. Zorrilla, P. Kaur, T. Ziyang, T. Lakshmikanth, P. Brodin, M. Occhipinti, C. Carlo-Stella, A. Santoro, P. Spiliopoulou, T.R.J. Evans, M. Maio
Journal: Annals of Oncology (2024)
678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Authors: C. Lemech, J.J. Luke, G.S. Falchook, M. Mckean, G. Kichenadasse, C. Teng, A.L. Vandross, M.A. Salkeni, V.G. Atkinson, J.J. Liu, A.M. Kennedy, J. Clark, M. Ryan, O. Schmidt-Kittler, D. Steinhubel, D. Wages, P. Komarnitsky, I. Puzanov
Journal: Annals of Oncology (2024)
660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Authors: L. Mansi, F. Ghiringhelli, C. de la Fouchardiere, B. You, E. Kalbacher, F. Bazan, C. Fagnoni Legat, G. Meynard, T. Maurina, A. Vienot, D. Vernerey, A. Meurisse, J-D. Fumet, M. Kroemer, A. Tanang, M. Rebucci-Peixoto, L. Spehner, S. Kim, O. Adotevi, C. Borg
Journal: Annals of Oncology (2024)
584P Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences
Authors: N. Crnovrsanin, S. Lakbir, R. de Wit, S. Ketelaars, N. Kok, P. Snaebjornsson, G. Meijer, S. Abeln, R. Fijneman
Journal: Annals of Oncology (2024)
645P Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
Authors: D. Liu, K. Arora, V. Makker, D. Buonocore, R. Shen, R. Yaeger, M.S. Ginsberg, R. Yeh, M.D. Offin, D. Solit, A.E. Drilon, C.M. Rudin, M.G. Kris, P. Razavi, J. Drago, S. Chandarlapaty, M. Berger, A.L. Ho, B.T. Li
Journal: Annals of Oncology (2024)
600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Authors: M.E. Elez Fernandez, S. Rosello Keranen, D. Paez, J. Jiménez Castro, F. Rivera Herrero, A. Ruiz-Casado, M.C. Riesco Martinez, C. Montagut Viladot, D. Coupez, M.P. Ducreux, C. Loly, J. Martin-Babau, H. Prenen, M. van den Eynde, C. Borg, P-J. Cuyle, A. de Haar-Holleman, J. Raimbourg, N. Bechar, J. Tabernero
Journal: Annals of Oncology (2024)
606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
Authors: F. Meric-Bernstam, Y. Naito, S. Gaillard, T. Shimoi, V. Chung, A.A. Davis, T. Proia, A. Ayyoub, M. Kulkarni, S. Upadhyay, N. Miller, N. Luheshi, A. Varga, D-Y. Oh, L. Mileshkin
Journal: Annals of Oncology (2024)
631P Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Authors: P.D. Soberanis Pina, S. Lheureux, H. Han, G. Shapiro, D.M. Provencher, L.S. Rosen, S. Sardesai, S. Taylor, D. Cescon, H.A. Alqaisi, S. Aparicio, P. Sabantini, T-I. Chao, C-E. Huang, M-C. Chen, L. Mahmud, X.Y. Ye, V. Bowering, A.M. Oza
Journal: Annals of Oncology (2024)
664P Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Authors: M.J. Lostes Bardaji, A. Mel Olano, O. Mirallas, D. Morchón Araujo, S. Pérez Fernandez, K. Raskina, V. Galvao, G. Alonso Casal, A. Oberoi, G. Pretelli, K.I. Rojas Laimito, B. Ortega Morillo, C. Ortiz Velez, E. Muñoz-Couselo, C. Viaplana, M. Vieito, I. Braña, R. Dienstmann, A. Hernando Calvo, E. Garralda
Journal: Annals of Oncology (2024)
612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
Authors: M. Vieito, M. Mckean, A.I. Spira, E. Rosen, J. Rodon, V. Moreno Garcia, V. Gambardella, O. Saavedra, S. Cousin, P. Cassier, I. Korakis, B.A. Van Tine, V.T-L. Ma, A. Ali, E. Hinojosa, R. Lobbardi, H. Liu, E. Hurh, L. Reyno, E. Buchbinder
Journal: Annals of Oncology (2024)
651P Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Authors: J. Yu, Y. Sun, T. Liu, S.G. Gao, Z. Guo, X. Liang, F. Ning, M. Zhang, Y. Zhang, N. Zhang, X. Wang, H. Zhao, Y. Hu, H. Wei, Y. Zhao, Y. Wang, Q. Shi, J. Li
Journal: Annals of Oncology (2024)
635P The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Authors: J. Wang, M. Zhuo, J. Xu, J. Zhong, B. Jia, R. Liu, C. Zhao, J. Li, C. Dong, L. Lai, S. Ma, B. Zhong, T. Zhang
Journal: Annals of Oncology (2024)
642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
Authors: Q. Zhou, Y-L. Wu, L. Wu, Y. Zhang, S. Ni, A. Liu, J. Li, G. Lin, J. Cui, W. Yao, J-M. Sun, Y. Zhang, H. Su, Y. Li, N. Yamamoto, Y. Kuboki, S-W. Han, Z. Wang, F. Qiu, L. Yang
Journal: Annals of Oncology (2024)
595P Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Authors: J. Desrame, V. Heinschild, C. Desauw, A.C. Fuerea, P. Artru, S. Javed, T. Papazyan, C. Ferté, M. Autheman, M. Valery, M.P. Ducreux
Journal: Annals of Oncology (2024)
634P First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Authors: X. Cheng, Z. Song, J. Yao, J. Yang, M. Wang, H. Zhou, T. Sun, Q. Wang, L. Wu, J. Miao, Y. Mi, J. Lin, H. Zhao, S. Xing, H. Wu
Journal: Annals of Oncology (2024)
620P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort
Authors: A. Naing, A.R. Khaki, S. Kummar, M.N. Al-Hallak, A.R. Abdul Razak, A.N. Diep, M. Schmidt, D. Maslyar, R. Vold, C.C. Hwang, D.M. Glatt
Journal: Annals of Oncology (2024)
616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors
Authors: E. Garralda, M.R. Patel, T.W. Kim, A.G. Sacher, M.D. Forster, A. Santoro, J. Desai, L.G. Paz-Ares, A. Falcon Gonzalez, M. De Miguel, S.E. Bowyer, R. Dziadziuszko, S.H. Kim, S-W. Han, M.G. Krebs, P. Lorusso, R. Cosman, J. Chang, T. Jun, W.H. Miller
Journal: Annals of Oncology (2024)
615MO Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
Authors: B.C. Cho, S. Lu, M.A. Lee, Z. Song, J.J.W. Park, S.M. Lim, Z. Li, J. Zhao, G. Richardson, Y. Zhang, J. Zhang, A. Liu, C. Chen, J. Wang, J. Chen, A. Wang, J. Zhang, Z.G. Chen, T.S.K. Mok, M.L. Johnson
Journal: Annals of Oncology (2024)
599TiP PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Authors: T. Sakakida, T. Masuishi, S. Mitani, M. Asayama, A. Makiyama, T. Shimura, H. Takeda, Y. Suwa, T. Yomoda, H. Mushiake, Y. Okumura, Y. Takano, M. Tajika, M. Ando, K. Muro, A. Mishima, C. Kudo, K. Murotani, H. Taniguchi
Journal: Annals of Oncology (2024)
641P Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors
Authors: A. Gil Torralvo, M. Vieito, J. Martinez Perez, G. Pretelli, V. Martinez, G.F. Boggio, C.M. Fernandéz, A. Hernandez, E. Cristoveanu, A. Belgrano, C. Kahatt, S. Fudio, A. Nieto, A. Redondo
Journal: Annals of Oncology (2024)
659P Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Authors: Z.A. Wainberg, Y. Cha, B. George, J.S. Grewal, J.R. Merchan, M. Mckean, H.P. Soares, T.D. Cruz, A.K. Moesta, T.M. Jahn, A.K. Singhal, C. Tribouley, S. Kongpachith, D.E. Afar, S. Mitra, D.R. Spigel, R. Balaraman
Journal: Annals of Oncology (2024)
594P Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Authors: A. Gandini, C. Gallois, H. Blons, C. Mulot, N. Agueeff, C. Lepage, R. Guimbaud, L. Mineur, J. Desrame, B. Chibaudel, A. de Reynies, T. André, P. Laurent-Puig, J. Taieb
Journal: Annals of Oncology (2024)